1. UCLA Integrated Substance Abuse Programs (ISAP)

2. CSAT MTP Project Goals: To study the clinical effectiveness of the Matrix Model To study the clinical effectiveness of the Matrix Model To compare the effectiveness of the Matrix model to other locally available outpatient treatments To compare the effectiveness of the Matrix model to other locally available outpatient treatments To establish the cost and cost effectiveness of the Matrix model compared to other outpatient treatments To establish the cost and cost effectiveness of the Matrix model compared to other outpatient treatments To explore the replicability of the Matrix model and challenges involved in technology transfer To explore the replicability of the Matrix model and challenges involved in technology transfer

3. Matrix Model vs TAU Rawson et al., 2004, Addiction 978 Methamphetamine users seeking treatment 978 Methamphetamine users seeking treatment CSAT multi-site study; 1998-2002 CSAT multi-site study; 1998-2002 Costa Mesa; San Diego; Hayward; Concord; Costa Mesa; San Diego; Hayward; Concord; San Mateo; Billings; Honolulu Matrix Model vs Treatment as Usual Matrix Model vs Treatment as Usual Random assignment Random assignment

4. Inclusion Criteria Males or females, 18 years of age or older. Males or females, 18 years of age or older. Must meet DSM-IV criteria for methamphetamine dependence Must meet DSM-IV criteria for methamphetamine dependence Willing to complete study forms and provide urine samples. Willing to complete study forms and provide urine samples. Able to understand and complete rating scales and follow instructions (with or without assistance). Able to understand and complete rating scales and follow instructions (with or without assistance).

5. Inclusion Criteria Able to understand and sign an informed consent (with or without assistance). Able to understand and sign an informed consent (with or without assistance). Have the ability to understand the English language, as well as the ability to participate in treatment and understand treatment materials (with or without assistance). Have the ability to understand the English language, as well as the ability to participate in treatment and understand treatment materials (with or without assistance).

6. Exclusion Criteria Current medical or psychiatric condition causing a degree of impairment or instability such that it would interfere with program participation and functioning and/or would preclude the primary treatment focus on the problem of methamphetamine dependence Current medical or psychiatric condition causing a degree of impairment or instability such that it would interfere with program participation and functioning and/or would preclude the primary treatment focus on the problem of methamphetamine dependence Candidates who meet DSM-IV criteria for dependence to opioids, alcohol, benzodiazepines or other sedative/hypnotics and who will require detoxification Candidates who meet DSM-IV criteria for dependence to opioids, alcohol, benzodiazepines or other sedative/hypnotics and who will require detoxification

7. Exclusion Criteria Candidates who have not used methamphetamine within 30 days prior to the study participation (participation begins one week prior to randomization), unless they were in a controlled environment (i.e. jail). Candidates who have not used methamphetamine within 30 days prior to the study participation (participation begins one week prior to randomization), unless they were in a controlled environment (i.e. jail). Candidates who have participated in any other chemical dependency treatment (inpatient rehab; therapeutic community; sober living facility; structured outpatient program) within 30 days of study participation for an episode of seven days or longer. Candidates who have participated in any other chemical dependency treatment (inpatient rehab; therapeutic community; sober living facility; structured outpatient program) within 30 days of study participation for an episode of seven days or longer.

8. Exclusion Criteria Candidates who are currently involved in a clinical research treatment project Candidates who are currently involved in a clinical research treatment project Candidates with any medical, legal, housing, or transportation problem which would preclude either safe or consistent participation Candidates with any medical, legal, housing, or transportation problem which would preclude either safe or consistent participation

9. TAU Steering committee decided between: Steering committee decided between: Standard TAU for all sites Standard TAU for all sites TAU for each site based on actual practice TAU for each site based on actual practice 8 TAUs resulted in: 8 TAUs resulted in: More relevance to sites More relevance to sites More variability More variability 8 studies 8 studies TAUs represented best available option vs minimal contact comparison TAUs represented best available option vs minimal contact comparison

10. Overview of TAUs Duration of Treatment Intensive Phase Individual Sessions Group Sessions 12-Step Program Involvement Site 1 8 weeks 1x/wk 4-8 wks 30-50 minutes 4x/wk 4-8 wks 3 hrs Families1x/wk required; 1x/wk 4-8 wks Site 2 12 weeks 1x/wk 12 wks 1 hr each 5x/wk x 2wk, 3x/wk x 2wks, 2x/wk x 8 wksRecommended Site 3 12 weeks 1x/wk 12 wks 1 hr eachNoneRecommended

11. Duration of Treatment Intensive Phase Individual Sessions Group Sessions 12-Step Program Involvement Site 4 16 weeks 1x/wk 16 wks 10-15 min 3x/wk 16 wks 1 hr required; 3x/wk 16 wks Site 5 12 weeks 1x/wk 12 wks 30-60 min 3x/wk x 12wks 2x/wk x 12wks 90 min 60-90 min required; 1x/wk 12 wks Site 6 12 weeks 1x/wk--2x/mo 12 wks 1 hr 2x/wk 12wks 90 min 60-90 min Recommended Overview of TAUs

12. Duration of Treatment Intensive Phase Individual Sessions Group Sessions 12-Step Program Involvement Site 7 16 weeks 1x/wk 16 wks 1 hr each 2x/wk 16 wks 2 hrsRecommended Site 8 12 weeks 2x/wk 12 wks 1 hr each 1x/wk 12 wks 2 hrsRequired 6 meetings Overview of TAUs

13. Baseline Demographics Age Age Male Male Education Education Meth use Meth use Marijuana use Marijuana use Alcohol use Alcohol use 32.8 years 55% 12.2 years 7.5 years 7.2 years 7.6 years

14. Ethnic Identification of Participants

15. Route of Methamphetamine Use

16. Weeks in Treatment **

17. Weeks Continuous Abstinence **

18. Mean Number of UA’s that were MA-free during treatment

19. Mean Number of Weeks in Treatment

20. Self-report of MA use during the past 30 days at baseline, discharge, and 6-month follow-up.

21. Urine Results: % Meth-free